• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于评估胶原诱导关节炎 Lewis 大鼠中 anakinra 作用的群体药代动力学-药效学-疾病进展模型。

Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.

机构信息

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14260, USA.

出版信息

J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):769-86. doi: 10.1007/s10928-011-9219-z. Epub 2011 Oct 16.

DOI:10.1007/s10928-011-9219-z
PMID:22002845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3407879/
Abstract

A population pharmacokinetic-pharmacodynamic-disease progression (PK/PD/DIS) model was developed to characterize the effects of anakinra in collagen-induced arthritic (CIA) rats and explore the role of interleukin-1β (IL-1β) in rheumatoid arthritis. The CIA rats received either vehicle, or anakinra at 100 mg/kg for about 33 h, 100 mg/kg for about 188 h, or 10 mg/kg for about 188 h by subcutaneous infusion. Plasma concentrations of anakinra were assayed by enzyme-linked immunosorbent assay. Swelling of rat hind paws was measured. Population PK/PD/DIS parameters were computed for the various groups using non-linear mixed-effects modeling software (NONMEM® Version VI). The final model was assessed using visual predictive checks and nonparameter stratified bootstrapping. A two-compartment PK model with two sequential absorption processes and linear elimination was used to capture PK profiles of anakinra. A transduction-based feedback model incorporating logistic growth rate captured disease progression and indirect response model I captured drug effects. The PK and paw swelling versus time profiles in CIA rats were fitted well. Anakinra has modest effects (I ( max ) = 0.28) on paw edema in CIA rats. The profiles are well-described by our PK/PD/DIS model which provides a basis for future mechanism-based assessment of anakinra dynamics in rheumatoid arthritis.

摘要

建立了群体药代动力学-药效动力学-疾病进展(PK/PD/DIS)模型,以描述在胶原诱导性关节炎(CIA)大鼠中阿那白滞素的作用,并探讨白介素-1β(IL-1β)在类风湿关节炎中的作用。CIA 大鼠接受载体、100mg/kg 阿那白滞素约 33 小时、100mg/kg 阿那白滞素约 188 小时或 10mg/kg 阿那白滞素约 188 小时皮下输注。通过酶联免疫吸附试验测定阿那白滞素的血浆浓度。测量大鼠后爪肿胀。使用非线性混合效应建模软件(NONMEM®Version VI)计算各组的群体 PK/PD/DIS 参数。使用视觉预测检查和非参数分层自举法评估最终模型。使用双室 PK 模型结合两个连续的吸收过程和线性消除来捕获阿那白滞素的 PK 曲线。纳入逻辑增长速率的基于转导的反馈模型用于捕获疾病进展,间接反应模型 I 用于捕获药物作用。CIA 大鼠的 PK 和爪肿胀与时间的曲线拟合良好。阿那白滞素对 CIA 大鼠的爪肿胀有适度的影响(I(max)=0.28)。我们的 PK/PD/DIS 模型很好地描述了这些曲线,为未来基于机制的类风湿关节炎中阿那白滞素动力学的评估提供了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/f29c9ef12784/nihms392751f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/373999e3f534/nihms392751f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/84e8bc6651c8/nihms392751f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/063b070d0b75/nihms392751f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/f29c9ef12784/nihms392751f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/373999e3f534/nihms392751f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/84e8bc6651c8/nihms392751f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/063b070d0b75/nihms392751f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a43/3407879/f29c9ef12784/nihms392751f4.jpg

相似文献

1
Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.用于评估胶原诱导关节炎 Lewis 大鼠中 anakinra 作用的群体药代动力学-药效学-疾病进展模型。
J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):769-86. doi: 10.1007/s10928-011-9219-z. Epub 2011 Oct 16.
2
Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach.阿巴西普在胶原诱导性关节炎大鼠中的药代动力学/药效学建模及疾病进展:群体方法。
J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12. doi: 10.1007/s10928-013-9341-1.
3
Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis.用于评估依那西普对胶原诱导性关节炎 Lewis 大鼠的影响的药代动力学-药效学疾病进展模型。
Pharm Res. 2011 Jul;28(7):1622-30. doi: 10.1007/s11095-011-0396-7. Epub 2011 Mar 1.
4
Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.甲氨蝶呤在健康和胶原诱导性关节炎大鼠中的药代动力学、药效学和毒性。
Biopharm Drug Dispos. 2013 May;34(4):203-14. doi: 10.1002/bdd.1838. Epub 2013 Apr 7.
5
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.骨保护素对核因子-κB 受体活化因子配体的抑制作用可防止骨丢失,而不影响两种大鼠关节炎模型的局部或全身炎症参数:与抗 TNFα 或抗 IL-1 治疗的比较。
Arthritis Res Ther. 2009;11(6):R187. doi: 10.1186/ar2879. Epub 2009 Dec 11.
6
Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats.建模在关节炎大鼠中地塞米松抗炎作用的性别差异。
Pharm Res. 2018 Sep 6;35(11):203. doi: 10.1007/s11095-018-2483-5.
7
Integration of efficacy, pharmacokinetic and safety assessment of interleukin-1 receptor antagonist in a preclinical model of arthritis.关节炎临床前模型中白细胞介素-1 受体拮抗剂的疗效、药代动力学和安全性评估的整合。
Regul Toxicol Pharmacol. 2011 Apr;59(3):461-70. doi: 10.1016/j.yrtph.2011.01.014. Epub 2011 Feb 12.
8
Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis.萘普生对胶原诱导性关节炎大鼠药代动力学、药效学及疾病进展影响的性别差异建模
Drug Metab Dispos. 2017 May;45(5):484-491. doi: 10.1124/dmd.116.074526. Epub 2017 Feb 28.
9
Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.激发试验的建模与设计:炎症和代谢生物标志物研究实例
Eur J Pharm Sci. 2015 Jan 25;67:144-159. doi: 10.1016/j.ejps.2014.11.006. Epub 2014 Nov 28.
10
Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis.类风湿性关节炎大鼠模型中皮质类固醇作用的建模II:地塞米松对胶原诱导性关节炎Lewis大鼠作用的机制药效学模型
J Pharmacol Exp Ther. 2008 Aug;326(2):546-54. doi: 10.1124/jpet.108.137414. Epub 2008 Apr 30.

引用本文的文献

1
The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.药物计量学在推进自身免疫性疾病治疗中的作用。
Pharmaceutics. 2024 Dec 5;16(12):1559. doi: 10.3390/pharmaceutics16121559.
2
Population Pharmacokinetic-Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats.利血平诱导大鼠肌痛模型的群体药代动力学-药效学分析
Pharmaceutics. 2024 Aug 21;16(8):1101. doi: 10.3390/pharmaceutics16081101.
3
Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase.基于血栓素合成酶不可逆抑制的HY-021068半机制模型
Front Pharmacol. 2020 Nov 30;11:588286. doi: 10.3389/fphar.2020.588286. eCollection 2020.
4
Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology.气道氧化还原稳态与炎症失调:从分子发病机制到呼吸病理学中的新兴治疗策略。
Int J Mol Sci. 2020 Dec 7;21(23):9317. doi: 10.3390/ijms21239317.
5
Comparative Assessment of the New PDE7 Inhibitor - GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach.新型 PDE7 抑制剂-GRMS-55 与利奥西呱在免疫相关性疾病动物模型中的比较评估:基于 PK/PD 模型的研究方法。
Pharm Res. 2020 Jan 2;37(2):19. doi: 10.1007/s11095-019-2727-z.
6
Effect of hypothermia on interleukin-1 receptor antagonist pharmacodynamics in inflammatory-sensitized hypoxic-ischemic encephalopathy of term newborns.亚低温对炎症反应性足月新生儿缺氧缺血性脑病中白细胞介素-1 受体拮抗剂药效学的影响。
J Neuroinflammation. 2018 Jul 30;15(1):214. doi: 10.1186/s12974-018-1258-6.
7
Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers.口服米格列奈对健康中国志愿者降血糖作用的药代动力学和药效学建模
BMC Pharmacol Toxicol. 2017 Jul 4;18(1):54. doi: 10.1186/s40360-017-0161-6.
8
Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis.萘普生对胶原诱导性关节炎大鼠药代动力学、药效学及疾病进展影响的性别差异建模
Drug Metab Dispos. 2017 May;45(5):484-491. doi: 10.1124/dmd.116.074526. Epub 2017 Feb 28.
9
Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.血浆白蛋白疾病相关变化对萘普生在雄性和雌性关节炎大鼠体内药代动力学的影响。
Drug Metab Dispos. 2017 May;45(5):476-483. doi: 10.1124/dmd.116.074500. Epub 2017 Feb 28.
10
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.托法替布缓释片每日一次给药方案的模型指导研发与注册
Clin Pharmacol Ther. 2017 Jun;101(6):745-753. doi: 10.1002/cpt.576. Epub 2017 Feb 9.

本文引用的文献

1
Paw inflammation model in dogs for preclinical pharmacokinetic/pharmacodynamic investigations of nonsteroidal anti-inflammatory drugs.用于非甾体抗炎药临床前药代动力学/药效学研究的犬爪炎症模型。
J Pharmacol Exp Ther. 2011 Aug;338(2):548-58. doi: 10.1124/jpet.110.178350. Epub 2011 Apr 27.
2
A clinical perspective of IL-1β as the gatekeeper of inflammation.从临床角度看白细胞介素-1β作为炎症的守门员。
Eur J Immunol. 2011 May;41(5):1203-17. doi: 10.1002/eji.201141550.
3
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.新型布鲁顿酪氨酸激酶(BTK)抑制剂在大鼠胶原诱导性关节炎中的抗关节炎作用及基于机制的药代动力学/药效学建模:BTK 磷酸化抑制与疗效的关系。
J Pharmacol Exp Ther. 2011 Jul;338(1):154-63. doi: 10.1124/jpet.111.181545. Epub 2011 Apr 26.
4
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.索拉非尼治疗实体瘤患者的群体药代动力学分析。
Br J Clin Pharmacol. 2011 Aug;72(2):294-305. doi: 10.1111/j.1365-2125.2011.03963.x.
5
Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis.用于评估依那西普对胶原诱导性关节炎 Lewis 大鼠的影响的药代动力学-药效学疾病进展模型。
Pharm Res. 2011 Jul;28(7):1622-30. doi: 10.1007/s11095-011-0396-7. Epub 2011 Mar 1.
6
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.白细胞介素-1 在炎症性疾病发病机制和治疗中的作用。
Blood. 2011 Apr 7;117(14):3720-32. doi: 10.1182/blood-2010-07-273417. Epub 2011 Feb 8.
7
Integration of efficacy, pharmacokinetic and safety assessment of interleukin-1 receptor antagonist in a preclinical model of arthritis.关节炎临床前模型中白细胞介素-1 受体拮抗剂的疗效、药代动力学和安全性评估的整合。
Regul Toxicol Pharmacol. 2011 Apr;59(3):461-70. doi: 10.1016/j.yrtph.2011.01.014. Epub 2011 Feb 12.
8
Rheumatoid arthritis.类风湿关节炎。
Lancet. 2010 Sep 25;376(9746):1094-108. doi: 10.1016/S0140-6736(10)60826-4.
9
Population pharmacokinetics of therapeutic monoclonal antibodies.治疗性单克隆抗体的群体药代动力学。
Clin Pharmacokinet. 2010 Oct;49(10):633-59. doi: 10.2165/11535960-000000000-00000.
10
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.目前生物性疾病修饰抗风湿药物治疗类风湿关节炎的证据:系统文献回顾为 EULAR 类风湿关节炎治疗建议提供依据。
Ann Rheum Dis. 2010 Jun;69(6):976-86. doi: 10.1136/ard.2009.126573. Epub 2010 May 6.